Roivant Sciences News and Activities

Roivant Sciences is owned by Sumitomo Chemical.

Sumitomo Chemical is one of the...

• Forbes Global 2000 (#1476);
• Nikkei 225;
• TOB Iconic 10,000;
• Topix.

Sumitomo Chemical is a company listed under the stock ticker 4005 (JP).

Sumitomo Chemical has a direct presence in 6 countries.

Sumitomo Chemical has 20 subsidiaries including Aetion, Aramis Biosciences and Asahi Chemical.

They are in:

• Biotechnology52%
• Chemicals24%
• Other24%

View the org chart displaying its 208 main executives

Most searched biographies at Roivant Sciences

• Matthew Gline, Chief Executive Officer
• James Momtazee, Director
• Keith Manchester, Director

Popular executive movements at Roivant Sciences

• Srini Ramanathan, Chief Development Officer, has left the company  (posted on November 4 2025).
• Ian Rosenblum has joined the company as Chief Information Officer  (posted on November 4 2025).

Create your alert
to follow the executive moves at Roivant Sciences.

Sumitomo Chemical has 2,414 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

• Nura Bio has just announced a $74 Million fundraising (posted on June 22 2026).
• Memento Medicines has just announced a $93 Million fundraising (posted on June 22 2026).
• Alvotech has just announced a $165 Million fundraising (posted on June 19 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Carl Gordon - Director at Odyssey Therapeutics
• Robert Gould - Board Member at Fulcrum Therapeutics

Learn more about the Biotechnology industry

Press releases by Roivant Sciences

• JPM Week 2026 is over. It was fantastic. Here’s why
• Roivant spinout heads to Phase 3 with ‘landmark’ data in immune skin disease
• Roivant immune drug significantly outperformed placebo in treating rare skin disease
• ‘Exciting’ brepocitinib data may open door for first targeted dermatomyositis drug
• Treatment for thyroid eye disease in an exciting era of growth
• Roivant and Priovant say skin drug brepocitinib succeeded in trial
• Immunovant reports more good data with first-gen FcRn drug, but says it's still focused on follow-up compound
• Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM) | Roivant Sciences Ltd.
• Roivant-backed VantAI and Halda line up $1B RIPTAC pact
• Exclusive: Roivant-backed VantAI debuts AI model Neo-1, taking ‘the big next step’ after AlphaFold 3
• View more press releases Close

Social media about Roivant Sciences

• Roivant Sciences on Wikipedia, Google News & Yahoo Finance
• Roivant Sciences on LinkedIn, X (Twitter) & YouTube